An interventional study of Tako Breath in Takotsubo Syndrome, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Takotsubo Cardiomyopathy with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Takotsubo Cardiomyopathy · United States.
Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, this one is the only one that started in 2021, is one of 6 with no phase, and was the 6th registered.
63 studies on the registry are indexed under Takotsubo Cardiomyopathy; 26 are open to participants now.
Browse Takotsubo Cardiomyopathy studies →3 of the 11 studies in Takotsubo Cardiomyopathy with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18–110
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Takotsubo Cardiomyopathy studies recruiting now, 19 (83%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 24 is below the median of 65 across 24 interventional studies indexed under Takotsubo Cardiomyopathy.
Median enrollment 17 across the 6 interventional studies, 190 across the 5 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 8 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 259 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 2 studies filed under Takotsubo Cardiomyopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Takotsubo Cardiomyopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03324529NYU Langone HealthAutonomic Modulation in Takotsubo Syndrome | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in laboratory testing to measure autonomic function. They will then undergo a 15-week program of device-guided breathing with remote measures of autonomic function obtained at home. Analysis will determine the reproducibility of home autonomic measures and the provide preliminary data to determine the efficacy of device-guided breathing on autonomic measures and quality of life in patients with takotsubo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10 patients with a confirmed history of takotsubo syndrome 10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness
Device: Tako Breath
Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (\<10 breaths/min) with prolonged exhalation.
Also known as: RESPeRATE
heart rate variability
Remote heart rate monitoring with an adhesive chest telemetry patch and biosensor wrist watch
Time frame: 10 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Jun 2027, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.